Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding
Status:
Unknown status
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
Two hundred & forty patients aged from 40 to 50 years - complaining of heavy menstrual
bleeding that is unresponsive to hormonal lines of treatment & requesting conservative
surgical approach- were randomized into 3 groups; group A (Surgicel group) in which 80
patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the
uterine cavity, group B (Thermal balloon ablation group) in which 80 patients underwent
thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure), group C
(Endometrial resection group) in which 80 patients underwent transcervical Hysteroscopic
endometrial resection.All patients were followed up over duration of 18 months following the
procedure (at 3,6,12 & 18 months). Primary outcome included amenorrhea rates